JFS Wealth Advisors LLC Acquires 921 Shares of Zoetis Inc. (NYSE:ZTS)

JFS Wealth Advisors LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 217.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,345 shares of the company’s stock after purchasing an additional 921 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Zoetis were worth $263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares during the period. Bank of New York Mellon Corp lifted its position in Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after purchasing an additional 178,303 shares during the period. Capital Research Global Investors boosted its holdings in Zoetis by 2.3% in the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after purchasing an additional 90,330 shares during the last quarter. Clearbridge Investments LLC grew its position in Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after purchasing an additional 166,517 shares during the period. Finally, Sarasin & Partners LLP raised its stake in Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after buying an additional 1,904,899 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS opened at $178.78 on Friday. The firm has a market cap of $81.00 billion, a P/E ratio of 34.99, a PEG ratio of 2.84 and a beta of 0.89. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a 50 day simple moving average of $188.95 and a two-hundred day simple moving average of $178.28. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.41 EPS. Equities analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. Zoetis’s dividend payout ratio is presently 33.86%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZTS shares. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Piper Sandler upped their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.